AntiCancer Japan, Inc.

AntiCancer Japan, Inc. is a contract research organization (CRO) specializing in non-clinical studies in oncology. By utilizing proprietary tumor models and bioluminescence technologies, they offer flexible efficacy evaluations in non-GLP environments. Their strength is in pharmaceuticals and regenerative medicine products.

Features of AntiCancer Japan, Inc.’s Non-Clinical Study Services

Extensive Collection of Unique Tumor Models Specialized in Oncology

AntiCancer Japan, Inc. focuses exclusively on oncology-related non-clinical research. They offer a wide range of tumor models, including CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, to provide practical data for therapeutic drug candidates.

In addition, the company can accommodate flexible design and advanced analytical items, such as luminescence and fluorescence imaging–based monitoring, combination therapy, and tumor relapse models. They have the platform that satisfies the quality and timely execution that are essential to oncology drug development.

Flexible Study Design for Exploratory Research (non-GLP)

Their research facilities are non-GLP (not compliant with Good Laboratory Practice). They have greater flexibility in exploratory research and early-stage screening.

In the early phases of drug development, flexibility and speed are often critical. AntiCancer Japan, Inc. conducts all of their studies in-house. This enables direct communication with researchers to design customized studies and models tailored to specific needs. Their strength lies on the ability to conduct trials and exploratory studies that may be difficult in GLP-compliant environments, especially during the initial developmental stage.

Interactive Support and Quick Response by a Expert Team

Rather than a large-scale organization,AntiCancer Japan, Inc. maintains a compact team of highly specialized professionals. This allows close communication and personalized support to each client.

After a thorough consultation with the client for their target goals and study requirements, the team fine-tunes study models and protocols accordingly.

With extensive expertise specifically in oncology, the company can provide practical, experience-based advice, which may be hard to find in general-purpose testing facilities. AntiCancer Japan, Inc. serves as a collaborative partner that offers companion-style contract services, working alongside clients to find the best, tailor-made solutions beyond standard protocols.

Examples of Disease Models at AntiCancer Japan, Inc.

CDX (Cell Line-Derived Xenograft) Model

The CDX model is a standard tumor model induced by transplanting human cancer cell lines subcutaneously or into organs of immunodeficient mice.

Leveraging its advanced oncology expertise, AntiCancer Japan, Inc.offers a wide variety of human cancer cell lines. Researchers can select the most suitable model for each cancer type, including solid tumors and leukemia.

The CDX model offers high reproducibility in tumor growth rate and drug responsiveness and is applicable to various studies, including efficacy evaluation of anticancer drugs, combination therapies, and comparison of administration routes. They can also do real-time monitoring through luminescence and fluorescence imaging with precise quantitative evaluation of treatment.

Reference: AntiCancer Japan, Inc. official website (http://www.anticancerjapan.com/research/index.html)

Case Studies of Non-Clinical Research at AntiCancer Japan

Fluorescence and Luminescence Imaging to Visualize the Effects of Cancer Drugs

AntiCancer Japan, Inc. uses tumor cells that express fluorescent and luminescent proteins to visualize tumor formation and treatment effects in mice. This imaging system enables non-invasive, time-course evaluation of tumor regression and regrowth following treatment.

The technique is applicable not only to subcutaneous tumor models but also to tumors implanted in the abdominal cavity, bladder, brain, liver, lungs, bone, and other organs, allowing dynamic observation across various cancer types.

Reference: AntiCancer Japan, Inc. official website (http://www.anticancerjapan.com/research/index.html)

Company Information